EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

EyePoint Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 06:30PM GMT
Release Date Price: €19.4 (-1.52%)
Wanhee Yeo JPMorgan Chase;Co.;Analyst

&-

Good morning, everyone. Thank you for joining the EyePoint Pharmaceuticals presentation on day three of the JPMorgan Healthcare Conference. I'm [Wanhee Yeo], from the JPMorgan Healthcare Investment Banking team. And it's my pleasure to be introducing you to Dr. Jay Duker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

Jay Duker EyePoint Pharmaceuticals Inc;President
CEO & Board Director

Thank you very much, and thanks all for coming and listening this morning. We are a publicly traded company. And as such, I will be making some forward-looking statements. And if you need any more information on that, please feel free to visit our website.

EyePoint in its heart is a drug delivery company to the back of the eye. Our lead product is called EYP-1901. It's a combination of vorolanib, which is a small molecule tyrosine kinase inhibitor that has activity against all the VEGF receptors and is placed into our patented Durasert E delivery system. E is for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot